The invention relates to novel antibodies that can bind specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, chimeric antibodies, and humanised antibodies, and to the amino acid and nucleic acid sequences coding for said antibodies. The invention relates to the use of said antibodies as medicament for the prophylactic and/or therapeutic treatment of cancer and in methods or kits for diagnosing diseases related to the overexpression of the protein CD151. The invention further relates to products and/or compositions comprising such antibodies combined with anticancer antibodies and/or agents or conjugated with toxins and/or radioelements, and to use thereof for the prevention and/or treatment of certain cancers.
